{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:00:32Z","timestamp":1792677632724,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1247,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["PG\/08\/020\/24617"],"award-info":[{"award-number":["PG\/08\/020\/24617"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["PG\/08\/020\/24617"],"award-info":[{"award-number":["PG\/08\/020\/24617"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Optimal management of heart failure with reduced ejection fraction (HFrEF) includes titration of guideline-directed medical therapy (GDMT) to the highest tolerated dose within the licensed range. During hospitalization, GDMT doses are often significantly altered, although it is unknown whether the cause of hospitalization influences this.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We recruited 711 people with stable HFrEF from specialist heart failure clinics and prospectively assessed events occurring during first unplanned hospitalization. Dose changes of ACE inhibitors or angiotensin receptor blockers (ACEi\/ARB), beta-blockers, mineralocorticoid receptor antagonists, and loop diuretics were recorded during 414 hospitalizations, categorized as due to decompensated heart failure, other cardiovascular causes, infection, or other non-cardiovascular causes. Most hospitalizations resulted in no change to GDMT. ACEi\/ARB dose was reduced in 21% of hospitalizations and was more common during non-cardiovascular hospitalization (25.4% vs. 13.9%; P = 0.005). ACEi\/ARB dose reduction was associated with older age and lower left ventricular ejection fraction at study recruitment, and poorer renal function, lower systolic blood pressure, higher serum potassium, and less frequent care from a cardiologist during admission. People experiencing ACEi\/ARB reduction had worse age-adjusted survival after discharge, without differences in heart failure re-hospitalization. De-escalation of beta-blockers occurred in 8% of hospitalizations, most often due to other non-cardiovascular causes; this was not associated with post-discharge survival or re-hospitalization with heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>De-escalation of HFrEF GDMT is more common during non-cardiovascular hospitalization and for ACEi\/ARB is associated with reduced survival. Post-discharge care plans should include robust plans to consider re-escalation of GDMT in these cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14051","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T05:24:08Z","timestamp":1657171448000},"page":"3298-3307","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Reduction of Heart Failure Guideline-Directed Medication During Hospitalization: Prevalence, Risk Factors, and Outcomes"],"prefix":"10.1093","volume":"9","author":[{"given":"Victoria","family":"Palin","sequence":"first","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, The University of Leeds , Clarendon Way, Leeds, LS2 9JT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Drozd","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, The University of Leeds , Clarendon Way, Leeds, LS2 9JT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis","family":"Garland","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, The University of Leeds , Clarendon Way, Leeds, LS2 9JT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anam","family":"Malik","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, The University of Leeds , Clarendon Way, Leeds, LS2 9JT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Straw","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, The University of Leeds , Clarendon Way, Leeds, LS2 9JT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"McGinlay","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leeds Teaching Hospitals NHS Trust , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Simms","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leeds Teaching Hospitals NHS Trust , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Kate","family":"Gatenby","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leeds Teaching Hospitals NHS Trust , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshuman","family":"Sengupta","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leeds Teaching Hospitals NHS Trust , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eylem","family":"Levelt","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, The University of Leeds , Clarendon Way, Leeds, LS2 9JT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus K.","family":"Witte","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, The University of Leeds , Clarendon Way, Leeds, LS2 9JT ,","place":["UK"]},{"name":"Medical Clinic 1, University Hospital Aachen, RWTH , Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Kearney","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, The University of Leeds , Clarendon Way, Leeds, LS2 9JT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7844-3600","authenticated-orcid":false,"given":"Richard M.","family":"Cubbon","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, The University of Leeds , Clarendon Way, Leeds, LS2 9JT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"2026012114155347600_ehf214051-bib-0001","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals","volume":"391","author":"Conrad","year":"2018","journal-title":"Lancet"},{"key":"2026012114155347600_ehf214051-bib-0002","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1001\/jamacardio.2019.3593","article-title":"Temporal trends and patterns in mortality after incident heart failure: a longitudinal analysis of 86 000 individuals","volume":"4","author":"Conrad","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2026012114155347600_ehf214051-bib-0003","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"2026012114155347600_ehf214051-bib-0004","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"2026012114155347600_ehf214051-bib-0005","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026012114155347600_ehf214051-bib-0006","doi-asserted-by":"crossref","first-page":"25","DOI":"10.15420\/cfr.2017:1:2","article-title":"Expert comment: is medication titration in heart failure too complex?","volume":"3","author":"Atherton","year":"2017","journal-title":"Card Fail Rev"},{"key":"2026012114155347600_ehf214051-bib-0007","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure","volume":"70","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026012114155347600_ehf214051-bib-0008","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114155347600_ehf214051-bib-0009","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026012114155347600_ehf214051-bib-0010","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCHEARTFAILURE.109.912683","article-title":"Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy","volume":"3","author":"Heywood","year":"2010","journal-title":"Circ Heart Fail"},{"key":"2026012114155347600_ehf214051-bib-0011","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012114155347600_ehf214051-bib-0012","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ejhf.252","article-title":"Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling","volume":"17","author":"G\u00fcder","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026012114155347600_ehf214051-bib-0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2018.06.011","article-title":"Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization","volume":"7","author":"Bhagat","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026012114155347600_ehf214051-bib-0014","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrcardio.2015.14","article-title":"The vulnerable phase after hospitalization for heart failure","volume":"12","author":"Greene","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"2026012114155347600_ehf214051-bib-0015","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1001\/jama.2010.533","article-title":"Relationship between early physician follow-up and 30-day readmission among medicare beneficiaries hospitalized for heart failure","volume":"303","author":"Hernandez","year":"2010","journal-title":"JAMA"},{"key":"2026012114155347600_ehf214051-bib-0016","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jacc.2008.03.048","article-title":"Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program","volume":"52","author":"Fonarow","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026012114155347600_ehf214051-bib-0017","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004675","article-title":"Initiation, continuation, or withdrawal of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction","volume":"6","author":"Gilstrap","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026012114155347600_ehf214051-bib-0018","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006746","article-title":"Infection-related hospitalization in heart failure with reduced ejection fraction","volume":"13","author":"Drozd","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2026012114155347600_ehf214051-bib-0019","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/heartjnl-2013-305294","article-title":"Prospective development and validation of a model to predict heart failure hospitalisation","volume":"100","author":"Cubbon","year":"2014","journal-title":"Heart"},{"key":"2026012114155347600_ehf214051-bib-0020","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1136\/heartjnl-2017-312539","article-title":"Socioeconomic deprivation and mode-specific outcomes in patients with chronic heart failure","volume":"104","author":"Witte","year":"2018","journal-title":"Heart"},{"key":"2026012114155347600_ehf214051-bib-0021","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026012114155347600_ehf214051-bib-0022","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2337\/dc17-1406","article-title":"Mortality reduction associated with \u03b2-adrenoceptor inhibition in chronic heart failure is greater in patients with diabetes","volume":"41","author":"Witte","year":"2018","journal-title":"Diabetes Care"},{"key":"2026012114155347600_ehf214051-bib-0023","article-title":"Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction","author":"Greene","year":"2021","journal-title":"Heart Fail Rev"},{"key":"2026012114155347600_ehf214051-bib-0024","article-title":"Early and short-term intensive management after discharge for patients hospitalized with acute heart failure: a randomized study (ECAD-HF)","author":"Logeart","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114155347600_ehf214051-bib-0025","article-title":"In-hospital initiation of quadruple medical therapy for heart failure: making the post-discharge vulnerable phase far less vulnerable","author":"Greene","year":"2021","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.14051","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.14051","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/5\/3298\/65352248\/eschf_9_5_3298.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/5\/3298\/65352248\/eschf_9_5_3298.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:19:01Z","timestamp":1769023141000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/9\/5\/3298\/8323043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,7,7]]},"published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14051","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10]]},"published":{"date-parts":[[2022,7,7]]},"assertion":[{"value":"2022-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}